Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: Performance in screening for colorectal cancer

European Journal of Gastroenterology and Hepatology

Volumn 19, Issue 10, 2007, Pages 878-882

  Mulder, Sanna A ^a,b   Van Leerdam, Monique E ^b   Van Vuuren, Anneke J ^b   Francke, Jan ^b   Van Toorenenbergen, Albert W ^b   Kuipers, Ernst J ^b   Ouwendijk, Rob J Th ^a  

^a IKAZIA HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Colorectal cancer screening; Immunochemical fecal occult blood test; Noninvasive screening test; Tumor markers; Tumor pyruvate kinase isoenzyme type M2

Indexed keywords

ISOENZYME; PYRUVATE KINASE;

ADULT; AGED; ARTICLE; CANCER SCREENING; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENTERITIS; FECES ANALYSIS; FEMALE; HUMAN; IMMUNOASSAY; IMMUNOCHEMISTRY; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; TUMOR LOCALIZATION;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; CARRIER PROTEINS; CLINICAL ENZYME TESTS; COLORECTAL NEOPLASMS; EPIDEMIOLOGIC METHODS; FALSE POSITIVE REACTIONS; FECES; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; OCCULT BLOOD; PYRUVATE KINASE; THYROID HORMONES; TUMOR MARKERS, BIOLOGICAL;

EID: 34548664828     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3282cfa49c     Document Type: Article

References (14)

1. Selby JV, Friedman GD, Quesenberry CP Jr, Weiss NS. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 1992; 326:653-657.
2. Frazier AL, Colditz GA, Fuchs CS, Kuntz KM. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA 2000; 284:1954-1961.
3. Hardt PD, Toepler M, Ngoumou B, Rupp J, Kloer HU. Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls. Anticancer Res 2003; 23:851-853.
4. Zhang B, Chen JY, Chen DD, Wang GB, Shen P. Tumor type M2 pyruvate kinase expression in gastric cancer, colorectal cancer and controls. World J Gastroenterol 2004; 10:1643-1646.
5. Hardt PD, Mazurek S, Toepler M, Schlierbach P, Bretzel RG, Eigenbrodt E, et al. Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. Br J Cancer 2004; 91:980-984.
6. Vogel T, Driemel C, Hauser A, Hansmann A, Lange S, Jonas M, et al. Comparison of different stool tests for the detection of cancer of the colon. Dtsch Med Wochenschr 2005; 130:872-877.
7. Winawer SJ, Zauber AG, Ho MN, O'Brien MJ, Gottlieb LS, Sternberg SS, et al. The National Polyp Study. Eur J Cancer Prev 1993; 2 (Suppl 2): 83-87.
8. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005; 129:422-428.
9. Winawer SJ, Zauber AG, O'Brien MJ, Ho MN, Gottlieb L, Sternberg SS, et al. Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. The National Polyp Study Workgroup. N Engl J Med 1993; 328:901-906.
10. Hardt PD, Ngoumou BK, Rupp J, Schnell-Kretschmer H, Kloer HU. Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastro-intestinal cancer. Anticancer Res 2000; 20:4965-4968.
11. Walkowiak J, Banasiewicz T, Krokowicz P, Hansdorfer-Korzon R, Drews M, Herzig KH. Fecal pyruvate kinase (M2-PK): a new predictor for inflammation and severity of pouchitis. Scand J Gastroenterol 2005; 40:1493-1494.
12. Greenberg PD, Bertario L, Gnauck R, Kronborg O, Hardcastle JD, Epstein MS, et al. A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing colonoscopy. Am J Gastroenterol 2000; 95:1331-1338.
13. Levi Z, Hazazi R, Rozen P, Vilkin A, Waked A, Niv Y. A quantitative immunochemical faecal occult blood test is more efficient for detecting significant colorectal neoplasia than a sensitive guaiac test. Aliment Pharmacol Ther 2006; 23:1359-1364.
14. Wong BC, Wong WM, Cheung KL, Tong TS, Rozen P, Young GP, et al. A sensitive guaiac faecal occult blood test is less useful than an immunochemical test for colorectal cancer screening in a Chinese population. Aliment Pharmacol Ther 2003; 18:941-946.